Physician profile
Jan Albert Janson
NPI 1124060298
$8,625.59
in general payments reported to CMS, 2019-2025
38 companies · $1,861 in 2025
The $1,861 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $929 · 2020: $417 · 2021: $301 · 2022: $1,225 · 2023: $1,885 · 2024: $2,007 · 2025: $1,861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,655 · Education: $98.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,654.79 |
| Education | $98.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,149.76 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,197.46 | 2019-2025 | Entyvio, Eohilia, Fosrenol |
| Janssen Biotech, INC. | $731.02 | 2019-2025 | Stelara, Tremfya, Simponi |
| Regeneron Healthcare Solutions, INC. | $520.02 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $408.99 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $408.89 | 2019-2025 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $307.10 | 2019-2025 | Ocaliva |
| Boston Scientific Corporation | $290.88 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Daiichi Sankyo INC. | $278.95 | 2019-2023 | Injectafer |
| Celgene Corporation | $245.44 | 2022-2024 | Zeposia |
| Gilead Sciences, INC. | $206.92 | 2019-2025 | |
| Celltrion USA INC. | $180.14 | 2024-2025 | Zymfentra, Vegzelma |
| Qol Medical, LLC | $174.91 | 2024-2025 | Sucraid, Sucraid |
| Pfizer INC. | $172.59 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $136.16 | 2022-2025 | Rebyota |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu INC. | $108.44 | 2020 | |
| Nestle Healthcare Nutrition INC. | $99.35 | 2021-2023 | |
| Tersera Therapeutics LLC | $94.15 | 2022-2023 | Xermelo |
| Genzyme Corporation | $91.79 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $83.01 | 2024-2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $72.19 | 2020-2024 | |
| Madrigal Pharmaceuticals | $67.15 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $66.94 | 2022-2025 | Sutab, Suflave |
| Alnylam Pharmaceuticals INC. | $64.84 | 2025 | Givlaari |
| Organon LLC | $62.48 | 2022-2023 | Renflexis, Hadlima |
| Novo Nordisk INC | $60.37 | 2025 | Wegovy |
| Amgen INC. | $57.26 | 2021-2023 | Avsola, Amjevita |
| Lilly USA, LLC | $50.83 | 2024-2025 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.96 | 2023-2024 | Cyltezo |
| Phathom Pharmaceuticals, INC. | $31.58 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $28.04 | 2024 | |
| Ucb, INC. | $25.53 | 2019 | |
| Intra-Sana Laboratories | $23.57 | 2022 | |
| Enterra Medical, INC. | $23.38 | 2025 | |
| Sandoz INC. | $19.38 | 2025 | Hyrimoz |
| Shire North American Group INC | $16.86 | 2019 | |
| W. L. Gore & Associates, INC. | $12.70 | 2022 | |
| Allergan, INC. | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Janson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.